Ignoring the nonsense: a phase II trial in cystic fibrosis

The Lancet

Volumn 372, Issue 9640, 2008, Pages 691-692

  Hyde, Stephen C ^a   Gill, Deborah R ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; CYCLIC AMP; EPITHELIAL SODIUM CHANNEL; GENTAMICIN; PLACEBO; PTC 124; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ARTICLE; CHLORIDE CHANNELOPATHY; CLINICAL TRIAL; CYSTIC FIBROSIS; DRUG BIOAVAILABILITY; DRUG EFFECT; GENE IDENTIFICATION; GENE MUTATION; GENE REPRESSION; HUMAN; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; STOP CODON; THORAX RADIOGRAPHY;

EID: 50149091319     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61169-1     Document Type: Note

References (13)

1. Mendell J.T., and Dietz H.C. When the message goes awry: disease-producing mutations that influence mRNA content and performance. Cell 107 (2001) 411-414
2. Holbrook J.A., Neu-Yilik G., Hentze M.W., and Kulozik A.E. Nonsense-mediated decay approaches the clinic. Nat Genet 36 (2004) 801-808
3. Boucher R.C. Evidence for airway surface dehydration as the initiating event in CF airway disease. J Intern Med 261 (2007) 5-16
4. The Cystic Fibrosis Genetic Analysis Consortium. Population variation of common cystic fibrosis mutations. Hum Mutat 4 (1994) 167-177
5. Johnson L.G., Olsen J.C., Sarkadi B., Moore K.L., Swanstrom R., and Boucher R.C. Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat Genet 2 (1992) 21-25
6. Howard M., Frizzell R.A., and Bedwell D.M. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med 2 (1996) 467-469
7. Clancy J.P., Bebok Z., Ruiz F., et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med 163 (2001) 1683-1692
8. Wilschanski M., Yahav Y., Yaacov Y., et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 349 (2003) 1433-1441
9. Mingeot-Leclercq M.P., and Tulkens P.M. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother 43 (1999) 1003-1012
10. Guan M.X., Fischel-Ghodsian N., and Attardi G. A biochemical basis for the inherited susceptibility to aminoglycoside ototoxicity. Hum Mol Genet 9 (2000) 1787-1793
11. Welch E.M., Barton E.R., Zhuo J., et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 447 (2007) 87-91
12. Hirawat S., Welch E.M., Elfring G.L., et al. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol 47 (2007) 430-444
13. Kerem E., Hirawat S., Armoni S., et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet (2008) 10.1016/S0140-6736(08)61168-X published online Aug 21.